Navigation Links
In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
Date:2/5/2009

SANTA MONICA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, explained that the Company is very close to becoming cash flow positive.

The complete interview is available at http://www.stoxrox.com/cbai-feb-b.mp3 . "2009 is a tipping point year for Cord Blood America. We will continue our organic growth strategy, adding new health insurance partners and possible new acquisitions, while continuing to reduce debt," Mr. Schissler said.

Cord Blood America's CEO said he was encouraged that more Federal spending on stem cell research under President Obama could lead to more stem cell therapies which, in turn, will lead to more families storing stem cells. "The stem cell agenda is front and center with the new Administration," Mr. Schissler said.

Cord Blood America's CEO also referenced the cover story of the new Time magazine, which cited breakthroughs using stem cells to treat Parkinson's, heart disease and diabetes. "Investors should understand, in storing umbilical cord blood stem cells, we have a significant biological annuity with low bad debt ratio, strong gross profits, and a low cost structure in place that will allow us to take full advantage of the expected increase in the storage of stem cells," the Company's founder said.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
5. Nastech to Host 2007 Analyst and Institutional Investor Day
6. Monsanto Company Sets Webcast and Analyst/Media Call for 2007 Fourth-Quarter and Fiscal-Year Financial Results
7. Nu Skin Enterprises to Hold 2007 Analyst Day
8. DURECT to Host Webcast in Conjunction with an Analysts Day on October 17
9. Webcast Alert: Isis Pharmaceuticals Announces its Analyst & Investor Day
10. Medco to Webcast Annual Analyst Day Conference
11. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... Malden, MA (PRWEB) , ... February 16, 2017 ... ... viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed ... The procedure was performed on a 55-year-old practicing female physician suffering from degenerative ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
Breaking Biology News(10 mins):